Pharmaceutical companies are spending close to $10 billion per year on direct-to-consumer advertising in the U.S. Only the entertainment industry spends more. Is that a good thing?
Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.
The FDA asked, and Eli Lilly and Company delivered. The company now hopes to secure an additional approval for orforglipron/Foundayo that covers the treatment of type 2 diabetes.
Of all lawsuits filed against patients in 2024 in one U.S. state, physician practices and other non-hospital healthcare entities accounted for 80% of cases. That’s a complete inversion from just six years prior.
In the three or so years since it burst into healthcare, ambient AI scribe technology has run away with the win in the market-uptake race. What has been the return on investment in all those software packages?
American Society of Echocardiography President David H. Wiener, MD, said one of his biggest goals is to help the group thrive in the face of ongoing workforce challenges. He also hopes to get new members involved.
The company has finalized an exclusive distribution deal with Future Medical Design to sell its stainless steel peripheral guidewires in the United States.
Caranx Medical is focused on using AI, robotics and other advanced technologies to expand patient access to life-saving procedures. This new software, for example, helps guide cardiologists through complex TAVR procedures.
Pharmaceutical companies are spending close to $10 billion per year on direct-to-consumer advertising in the U.S. Only the entertainment industry spends more. Is that a good thing?